India, Nov. 6 -- Moderna, Inc. (MRNA), a biotechnology company focused on mRNA medicines and vaccines, reported Friday third-quarter 2026 financial results, returning to profitability as revenue increased 29% year over year to $1.3 billion.
The company raised its full-year revenue growth outlook and improved its research and development expense forecast. Shares gained 4.04%.
Third Quarter 2026 Financial HighlightsFor the quarter ended September 30, 2026, total revenue increased 29% to $1.313 billion from $1.016 billion in the prior-year quarter, primarily driven by higher COVID-19 vaccine sales in international markets.
U.S. revenue totaled $780 million, while international revenue reached $533 million. Net product sales increased to $1....